Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7524958 | Le Pharmacien Hospitalier et Clinicien | 2018 | 6 Pages |
Abstract
For ICD implantation to remain financially feasible, the proportion of high-cost ICDs (subcutaneous and triple-chamber) should not exceed 50Â % in order not to increase the cost of the procedure per patient in comparison to 2011. The DRG-based budget system thus penalizes centers fitting more of the more expensive devices, and fails to take account of the long-term cost savings associated with subcutaneous ICDs, which would be interesting to assess.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
N. Duret-Aupy, J. Capsec, N. Clémenty, P. Meunier, S. Benaïn,